Amgen Inc.

My name is Jason, and I'll be the conference facilitator today for Amgen's fourth quarter full year 2022 financial results conference call. All lines have been placed on mute event any background noise. There will be a question and answer session at the conclusion of the last featured prepared remarks. In order to ensure that everyone has a chance to participate, we would like to request that you limit yourself to asking one question during the Q&A session. To ask a question, please press star and then the number one on your telephone keypad. To withdraw your question, please press star two. I would now like to introduce Mr. Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.

Okay, thank you, Jason. Good afternoon, everyone, and welcome to our call to discuss the results for Q and full year 2022. 2022 was once again a year exemplified by great execution, despite some of the macro challenges. Our Chairman and CEO, Bob Bradway, will make some opening comments. followed by prepared comments from other members of our senior leadership team. You should have received a link to our slides that we have posted. Through the course of our discussion, we will make some forward-looking statements and use non-GAAP financial measures to describe our performance, and just a reminder that actual results can vary materially. So with that, I would like to turn the call over to Bob.

Okay. Thank you, Arvind, and hello, everyone, and thank you for joining our call. We're beginning the year feeling confident about the long-term growth outlook for our business, and let me offer five reasons why. First, we have a number of innovative, volume-driven products that still have plenty of room to run, and we saw that in 2022. Repatha, Prolia, and Avenity each generated double-digit sales and volume growth in the fourth quarter and for the full year. We expect continued growth from these products in 2023 and beyond, with Repatha in particular helped by important new data from the 4EA Open Label Extension Study and new prescribing guidelines. Otesla delivered 7% volume growth in both the fourth quarter and the full year, benefiting from a label expansion that gives us the opportunity to reach millions of new patients in the U.S. with mild to moderate psoriasis. Lumicrast and Tespire collectively contributed more than $450 million in full-year sales, and we're pursuing additional indications for both products. We're especially pleased to see Tespire being utilized by patients across all types of severe asthma. Murdo will share more about the performance of our inline products in a moment. Second, we moved six first-in-class molecules into Phase III or potentially registration-enabling trials in 2022, including Olpaziran for LP little a, rocatinlamab for atopic dermatitis, Tespire in eosinophilic esophagitis, and, of course, bimertuzumab, tarlatumab, and Blinsido in cancer. We've also begun enrolling patients in a Phase II trial for AMG133. Based on early data, this molecule, with its unique mechanism of action, Looks like it may have an attractive profile for the treatment of obesity. And more on our pipeline from Dave Reese in a moment. Third, we have an industry-leading biosimilars business that will contribute to our growth over time. In 2022, we delivered positive phase three data for our biosimilar candidates to ILEA, Solaris, and Stellara, positioning us to be in the first wave of these launches, which we know is critical to success. We're also less than 24 hours into the launch of Amgivita in the US. And Amgivita is the leading biosimilar to Humira internationally. And with a five-month lead over the next entrant, we're well positioned for success in the US. All told, we have six more biosimilar launches planned in the US and markets around the world between now and the end of the decade, making this another source of long-term growth for us. Fourth, we've often said that we would look to licensing and acquisitions in our stated areas of strategic interest, and that's what we've done, building on our decades of experience in inflammation with two significant transactions that will strengthen our presence in this space. Through the acquisition of chemocentrics, we added TAVNEOS, a first-in-class treatment for ANCA-associated vasculitis, and we're off to a strong start there. Our announced acquisition of Horizon Therapeutics will add several additional first-in-class early-in-life cycle biologic medicines, including Tepeza, Cristexa, and Uplizna, that will add to our growth profile through 2030 and beyond. We're working our way through the regulatory review processes for that deal and are confident that the deal poses no anti-competitive matters. And we have received a second request from the USFTC and we'll work with them to answer their questions while remaining optimistic that we can complete the deal in the first half of the year. Finally, we've stayed true to our capital allocation priorities, investing in our business to drive long-term growth while also returning capital to our shareholders through share repurchases and a growing dividend. You'll hear more from Peter on this shortly. And everything we achieved last year and everything we will achieve going forward is due to the hard work and commitment of our people. They're passionate about our mission to serve patients. They're clear on how their work contributes to our success, and they're ready to seize the opportunities and meet the challenges that await us, and I'm grateful to all of them. I look forward to your questions a little later on, but now let me turn the call over to Murdo.